{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=doxorubicin&page=8", "query": { "intervention": "doxorubicin", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 1379, "total_pages": 138, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=doxorubicin&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=doxorubicin&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T19:43:42.772Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01101594", "title": "A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "hLL1-DOX (the doxorubicin conjugate of milatuzumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2010-07", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2021-08-16", "last_synced_at": "2026-10-17T19:43:42.772Z", "location_count": 5, "location_summary": "Orlando, Florida • Atlanta, Georgia • Hackensack, New Jersey + 2 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01101594" }, { "nct_id": "NCT00407888", "title": "Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-positive Breast Cancer", "HER2-positive Breast Cancer", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "paclitaxel albumin-stabilized nanoparticle formulation", "type": "DRUG" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 60, "start_date": "2006-05", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2017-08-31", "last_synced_at": "2026-10-17T19:43:42.772Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00407888" }, { "nct_id": "NCT01296659", "title": "Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Soft Tissue Sarcoma" ], "interventions": [ { "name": "ridaforolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2011-02", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2012-07-12", "last_synced_at": "2026-10-17T19:43:42.772Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01296659" }, { "nct_id": "NCT00433537", "title": "Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Contiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage IV Mantle Cell Lymphoma" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Autologous stem cell transplantation (ASCT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2007-05", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2014-10-30", "last_synced_at": "2026-10-17T19:43:42.772Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00433537" }, { "nct_id": "NCT02700022", "title": "A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-cell Lymphoma", "Follicular Lymphoma", "Burkitt Lymphoma" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2016-10", "completion_date": "2017-08-18", "has_results": false, "last_update_posted_date": "2017-11-20", "last_synced_at": "2026-10-17T19:43:42.772Z", "location_count": 2, "location_summary": "Duarte, California • Chapel Hills, North Carolina", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chapel Hills", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02700022" }, { "nct_id": "NCT00002715", "title": "Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "Stanford V regimen", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Mechlorethamine hydrochloride", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 50, "start_date": "1989-04", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2020-08-12", "last_synced_at": "2026-10-17T19:43:42.772Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002715" }, { "nct_id": "NCT00021255", "title": "Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Herceptin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 3222, "start_date": "2001-04", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-11-15", "last_synced_at": "2026-10-17T19:43:42.772Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00021255" }, { "nct_id": "NCT00248248", "title": "DOXIL for Consolidation Therapy in Ovarian Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasm" ], "interventions": [ { "name": "liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Southeastern Gynecologic Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 45, "start_date": "2005-10", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2011-10-12", "last_synced_at": "2026-10-17T19:43:42.772Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00248248" }, { "nct_id": "NCT02531308", "title": "Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2015-07", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2022-09-28", "last_synced_at": "2026-10-17T19:43:42.772Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02531308" }, { "nct_id": "NCT05996185", "title": "Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T Cell Lymphoma", "T-cell Lymphoma" ], "interventions": [ { "name": "Mogamulizumab", "type": "DRUG" }, { "name": "DA-EPOCH Protocol", "type": "DRUG" }, { "name": "CHOEP protocol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2024-10-09", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-10-17T19:43:42.772Z", "location_count": 2, "location_summary": "New Haven, Connecticut • New York, New York", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05996185" } ] }